VAXIMM receives grant to expand pipeline of oral cancer vaccines

08-Oct-2012 - Switzerland

VAXIMM AG announced that its German subsidiary VAXIMM GmbH has been awarded a grant from the BioRN cluster “Cell-based and Molecular Medicine” to expand its oral T-cell vaccine technology platform. The cluster competition is a program of Germany´s Federal Ministry of Education and Research (BMBF) to promote top-notch innovation in Germany.

VAXIMM’s lead candidate VXM01 is an oral T-cell vaccine, which targets the tumor vasculature. It is currently in Phase I/II clinical evaluation in pancreatic cancer patients at the Heidelberg University Hospital. The funding from the cluster program will be used to develop additional cancer vaccines complementary to VXM01, which are based on the same oral T-cell vaccine technology. A second candidate (VXM06), which targets an undisclosed, abundant, tumor-specific antigen, is already in preclinical development. Two further product candidates are at discovery stage.

VAXIMM’s oral T-cell vaccine technology has a number of advantages. The platform can easily and rapidly generate new vaccines, including multivalent vaccines. The resulting products combine oral efficacy with safety and excellent tolerability. Moreover, the vaccines do not require a complex manufacturing infrastructure.

“We are pleased about the recognition of the potential of our oral T-cell vaccination platform,” said Dr. Heinz Lubenau, General Manager of VAXIMM GmbH. “It allows leveraging our work on VXM01 to add additional products to our promising pipeline.”

https://www.bionity.com/en/news/140023/vaximm-receives-grant-to-expand-pipeline-of-oral-cancer-vaccines.html